Background

Age‐related macular degeneration (AMD) is one of the leading causes of permanent blindness worldwide. The current mainstay of treatment for neovascular AMD (nAMD) is intravitreal injection of anti‐vascular endothelial growth factor (anti‐VEGF) agents: aflibercept, ranibizumab, and off‐label bevacizumab. Injections can be given monthly, every two or three months ('extended‐fixed'), or as needed (pro re nata (PRN)). A variant of PRN is' treat‐and‐extend'whereby injections are resumed if recurrence is detected and then delivered with increasing intervals. Currently, injection frequency varies among practitioners, which underscores the need to characterize an optimized approach to nAMD management.

Objectives

To investigate the effects of monthly versus non‐monthly intravitreous injection of an anti‐VEGF agent in people with newly diagnosed nAMD.